Delcath Systems, Inc. (DCTH) News
Filter DCTH News Items
DCTH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DCTH News Highlights
- For DCTH, its 30 day story count is now at 3.
- Over the past 21 days, the trend for DCTH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest DCTH News From Around the Web
Below are the latest news stories about DELCATH SYSTEMS INC that investors may wish to consider to help them evaluate DCTH as an investment opportunity.
Insider Buying: Chief Medical Officer Vojo Vukovic Acquires 40,000 Shares of Delcath Systems ...In a notable insider transaction, Chief Medical Officer Vojo Vukovic has recently increased his stake in Delcath Systems Inc (NASDAQ:DCTH) by purchasing 40,000 shares of the company's stock. |
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma ResearchDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Melanoma Research. The publication, entitled "Quality of Life After Melphalan Hepatic Perfusion for Uveal Melanoma", was based on an independent clinical study conducted by investigators from University Hospital Southampton, UK and focused on the impact of melphalan percutaneous hepatic |
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals. |
Delcath Systems Reports Third Quarter 2023 Results and Provides Business UpdateDelcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023. |
Delcath Systems to Host Third Quarter 2023 Results CallDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. |
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal CancersDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of an article entitled "Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study" in the peer reviewed oncology journal Cancers. CS-PHP utilizes CHEMOSAT, Delcath's proprietary European CE Marked Hepatic Delivery |
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor ConferenceDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023. |
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the Roth MKM Healthcare Opportunities Conference in New York. Delcath CEO, Gerard Michel will present on October 12 at 11:45 AM ET. |
These 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say AnalystsLet’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi |
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual MeetingDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent investigators on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting held in Copenhagen, Denmark. |